Effects of vitamin D supplementation on circulatory YKL-40 and MCP-1 biomarkers associated with vascular diabetic complications: A randomized, placebo-controlled, double-blind clinical trial.

Plain-language guide to PMID 31425951 (2019): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 48 patients.

Key Facts

PMID: 31425951
Journal: Diabetes & metabolic syndrome
Year: 2019
Study type: Randomized Controlled Trial
Authors: Omidian M et al. (9 authors)
DOI: 10.1016/j.dsx.2019.07.047

What This Study Did, in Plain Language

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

Diabetic patients predispose to vascular diseases such as nephropathy, and retinopathy.

Poor adherence to medical treatment and dietary recommendations in uncontrolled diabetes leads to vascular damages.

YKL-40 and Monocyte chemoattractant protein-1 (MCP-1) are considered to exert crucial role in diabetes and its complications.

Who Took Part

The abstract describes 48 patients taking part.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The patients were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Blinding on both sides kept the patients and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

Some patients received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

Before and after intervention, serumYKL-40, MCP-1, insulin, IL-6, TNF-α, 25- (OH) vitamin D and HbA1c were measured.

What Was Measured

The subject headings attached to it are Biomarkers, Chemokine CCL2, Chitinase-3-Like Protein 1, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Dietary Supplements and Prognosis.

The authors tagged it with the keywords Diabetic complications, Inflammation, Monocyte chemoattractant protein-1, Vitamin D and YKL-40.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 48 patients.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2019 (Diabetes & metabolic syndrome), a journal based in Netherlands.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.

Our Notes on the Compound

Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.

Vitamin D, K2, Magnesium and Zinc in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.